Proposed Changes to the CDC Could Influence Scientific Independence
Legislative proposals and developments related to drug pricing, vaccine policy, scientific oversight, and more showcase concerns that politicization could outweigh evidence.
In this edition of AcademyHealth’s Situation Report, we examine new proposals with the potential to reshape drug pricing and affordability, as well as the federal research enterprise – including concerns about political influence over scientific independence and timeliness. We also explore concerns related to a new charter for the Advisory Committee on Immunization Practices (ACIP) which could undermine the intended function of the agency and favor ideology over expertise. These are clear examples of the ways policy changes are shaping both the health workforce and everyday people who receive care. Read on to learn from a former CDC leader on the personal toll RIF’s and workforce challenges have on the field.
In today’s issue:
New ACIP Charter Widens Member Criteria and Focuses on Vaccine Alternatives
Proposed CDC Science Office Raises Questions About Oversight and Scientific Independence
Court Blocks Student Loan Rule Affecting Health Workforce Pipeline
Senator Cassidy Proposes Sweeping Overhaul of the 340B Drug Discount Program
Why Health Care Wait Times Are Used as Political Talking Point
What Remains When Work Is Interrupted: A Leader’s Reflection
New ACIP Charter Widens Member Criteria and Focuses on Vaccine Alternatives
The new charter for the Advisory Committee on Immunization Practices (ACIP) undermines the critical role of the panel in recommending the use of new vaccines and instead expands its responsibilities to focus on alternative methods for disease prevention. While the earlier charter prioritized strong vaccine research experience in the selection of ACIP members, the new charter broadens and loosens qualification requirements. This change could potentially allow members with limited vaccination and vaccine policy expertise to determine vaccine recommendations for the entire country. The updated version of the charter was posted on CDC’s website on June 24.
The new charter is part of the broader restructuring efforts of Secretary Kennedy. It has been a year since Secretary Kennedy fired members of the ACIP in an overt attempt to restructure the panel with vaccine skeptics lacking vaccine expertise. The court ruled that the new members were unqualified, challenging Kennedy’s reconfiguration of the committee. The administration has appealed against the ruling, and the new charter is seen as a strategy to legitimize the new panel and bypass the legal challenges.
The updated charter could shift the focus toward questioning vaccine safety instead of promoting safe vaccine use, jeopardizing the health of the American people. The changes could impact vaccine recommendations for programs like Vaccines for Children that ensure uninsured children have free access to all recommended immunizations. Under the new charter, political influence could outweigh evidence-informed vaccine recommendations.
Proposed CDC Science Office Raises Questions About Oversight and Scientific Independence
A proposed restructuring at the Centers for Disease Control and Prevention (CDC) could give political appointees greater oversight of scientific communications produced by the agency. According to reports, a new office, the Executive Advisory, Science, and Operations Unit, would review scientific publications, including articles published in the CDC’s Morbidity and Mortality Weekly Report (MMWR), submissions to peer-reviewed journals, and agency briefings related to public health preparedness. The office would report to CDC leadership through the agency’s chief of staff.
Supporters may view the proposal as a way to improve coordination and oversight of agency communications. However, critics have raised concerns that placing additional review authority within a politically appointed structure could affect the independence and timeliness of scientific information released by the agency. The proposal remains uncertain, as CDC officials reportedly continue to search for funding and the office has not yet been formally established.
Changes to how federal health agencies evaluate and disseminate scientific findings could influence public trust, data transparency, and the speed with which evidence reaches policymakers, providers, and communities. For researchers, the proposal raises questions about how scientific findings move from federal agencies to the public and whether new layers of review could influence that process.
Court Blocks Student Loan Rule Affecting Health Workforce Pipeline
A federal judge temporarily blocked the U.S. Department of Education from implementing part of a new student loan rule that would have taken effect July 1 under the One Big Beautiful Bill Act (H.R. 1). H.R. 1 establishes new federal student loan borrowing limits, including a lifetime cap of $100,000 for most graduate programs and $200,000 for professional programs, while phasing out the Graduate PLUS loan program. The department’s rule defined which programs qualified as “professional” degrees eligible for the higher borrowing limit, but excluded nursing, physician assistant, public health, and several other health professions.
The court found the department likely exceeded its legal authority by narrowing the definition of a “professional degree” in a way not authorized by Congress. As a result, the rule’s definition of eligible professional programs is temporarily blocked while the case proceeds. AcademyHealth has previously warned that these borrowing caps and the exclusion of key health professions could make advanced education less affordable, limiting access to careers in nursing, public health, and other essential health fields at a time when workforce shortages persist. AcademyHealth has also noted that excluding nursing from the professional degree designation risks “deprofessionalizing” the field, creating additional barriers to graduate education, worsening faculty shortages, and reducing the pipeline of future clinicians.
The ruling provides temporary relief for students in nursing, physician assistant, public health, and other affected graduate programs by preventing the department’s narrower definition from taking effect while the legal challenge continues. However, the judge emphasized that H.R. 1’s statutory borrowing caps remain in place, even though the department’s current rule cannot be enforced. The outcome of the case will determine how those borrowing limits are applied and could have significant implications for the affordability of health professions education, the public health workforce, and the nation’s ability to recruit and retain the clinicians and public health professionals needed to meet growing health care demands
Senator Cassidy Proposes Sweeping Overhaul of the 340B Drug Discount Program
Outgoing Senate HELP Committee Chair Bill Cassidy has released a discussion draft of legislation that would make the most significant statutory changes to the 340B Drug Pricing Program in more than a decade. The program requires pharmaceutical manufacturers to provide discounted drugs to certain hospitals, clinics, and safety-net providers that serve large numbers of low-income and uninsured patients. Participating providers can use those savings to help support care for vulnerable populations and offset uncompensated care costs.
The proposal would introduce new reporting requirements, revise eligibility standards, establish clearer definitions for who qualifies as a 340B patient, and limit the number of contract pharmacies, retail pharmacies that dispense discounted drugs on behalf of participating hospitals and clinics, that providers may use. It would also allow manufacturers to provide discounts through a rebate model, meaning providers would initially pay full price for a drug and receive reimbursement later after submitting claims data. Supporters argue these changes would improve transparency, accountability, and oversight in a program that has expanded substantially in recent years. Hospital groups, however, warn that the reforms could reduce savings that safety-net providers rely on to maintain services and support patient access to care.
Senator Cassidy is seeking stakeholder feedback before any legislation is introduced. Comments are due August 28, 2026, and can be submitted to 340bforpatients@help.senate.gov. For researchers and health care organizations, the request presents an opportunity to inform the debate with evidence on how the program functions in practice and how proposed changes may affect patients, providers, and health system costs.
Why Health Care Wait Times Are Used as Political Talking Point
So far, AcademyHealth’s Pain Points video series on American health care has covered what causes long wait times and the policies behind those wait times. Our latest video rounds out this conversation by getting into the way we talk about wait times, and how this is often politicized. Watch this week’s episode to learn how wait times are used as a rhetorical weapon in political debate. The previous two episodes on wait times, as well as three episodes on the cost of care, are available here.
What Remains When Work Is Interrupted: A Leader’s Reflection
In our next reflection for the Work Interrupted: Voices from the Field blog series, we continue to highlight voices from across public health and health services research navigating disruption and transition.
Dr. Debra Houry reflects on her leadership at the CDC during a period of significant change, writing about the tension between loyalty and integrity, the challenges of leading through uncertainty, and the deeply personal process of redefining purpose beyond a title.
Her reflection offers a grounded and timely perspective on what it means to move forward with intention when a chapter ends unexpectedly.
Read “When Work Is Interrupted: Finding Purpose Beyond a Title.”